UNSPSC 51263404: Bretylium

This classification denotes an alpha-adrenergic blocking agent with the molecular formula C11H17BrN, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RZR75EQ2KJ, chemically known as benzenemethanaminium, 2-bromo-n-ethyl-n,n-dimethyl-, salt with 4-methylbenzenesulfonic acid (1:1) but generally known as bretylium, which bears US NIH Compound Identifier 2431. Bretylium most often comes in base, bromide, p-toluenesulfonate, and tosylate forms.

UNSPSC 51263404 Bretylium is a Commodity code that represents emergency pharmaceutical products, specifically medications used in acute medical interventions. The recent state and local opportunities tagged to this code show a significant mismatch with its nominal scope: the Seminole County solicitation centers on naloxone and drug deactivation systems rather than bretylium, while the Texas HHS RFI addresses direct-to-manufacturer prescription fulfillment strategies across a broader pharmacy benefit spectrum. The code shows little relevant recent activity aligned with bretylium as a discrete pharmaceutical product. State and local procurement under this code tier appears minimal, with issuing bodies predominantly county health departments and state health and human services agencies when activity does occur.

Geographically, the sparse recent record reflects activity in Florida and Texas. The Seminole County, Florida IFB (IFB60459723LAS) issued June 30, 2026, sought annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries and a response deadline of July 26, 2023—a historical inconsistency in the source data. The Texas Health and Human Services Commission RFI (HHS0017013) posted April 3, 2026, explores direct-to-manufacturer prescription contracting models but does not target bretylium specifically. The mismatch between the code taxonomy and recent solicitation content suggests that state and local procurement offices may be applying this Commodity code inconsistently, or that bretylium procurement activity has shifted toward bundled pharmaceutical procurement mechanisms rather than discrete-product buys. Pursuit under this code warrants clarification of actual product scope in pre-bid communication with issuing bodies.